Edit |   |
Antigenic Specificity | PD-L1/PDCD1LG1/CD274/B7-H1 (Cancer Immunotherapy Target) |
Clone | [PDL1/2744] |
Host Species | Mouse |
Reactive Species | human, mouse |
Isotype | IgG1, kappa |
Format | purified |
Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
Concentration | n/a |
Applications | ELISA (EIA), Western Blot (WB) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Specificity: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein c |
Immunogen | Immunogen: Recombinant fragment of human CD274 protein (around aa39-191) (exact sequence is proprietary) |
Other Names | [B7 homolog 1; B7-H1; CD274; PD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; Programmed cell death 1 ligand 1] |
Gene, Accession # | [CD274], Gene ID: 29126, NCBI: NP_001254635.1, UniProt: Q9NZQ7 |
Catalog # | MBS4380958 |
Price | $190, $340, $340 |
Order / More Info | PD-L1/PDCD1LG1/CD274/B7-H1 (Cancer Immunotherapy Target) Antibody from MYBIOSOURCE INC. |
Product Specific References | Dong, H., et al. 1999. Nat. Med. 5: 1365-1369. |